Down Syndrome Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Eisai, Roche, Elan Pharma, Aelis Farma, AC Immune SA, Eisai Inc., Forest Lab

DelveInsight’s “Down Syndrome Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Down Syndrome, historical and forecasted epidemiology as well as the Down Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Down Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Down Syndrome Market Forecast

Some of the key facts of the Down Syndrome Market Report: 

• The Down Syndrome market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• As per the Minnesota Health Department (2023), the most frequent genetic cause of developmental delay in the United States is Down syndrome, which affects 1 in 800-1000 live births. It also stated that there are three different kinds of Down syndrome: mosaicism accounts for around 1% of instances, translocation accounts for roughly 4%, and trisomy 21 (nondisjunction) accounts for 95% of cases.
• Approximately 400,000 Americans have been diagnosed with Down syndrome, and over 6,000 newborns are born in the US each year with the condition, according to the DSAGSL organization (2022).
• In Japan, the total prevalence was 5.82 Down syndrome births per 10,000 live births, according to Hoshi et al.
• Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Forest Laboratories, Eisai Co., Hoffmann-La Roche, Elan Pharma, Life Molecular Imaging, Cidara Therapeutics, and others
• Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, Memantine, E2020, RG1662, ELND005, Florbetaben (BAY94-9172), CD101, and others
• The Down Syndrome epidemiology based on gender analyzed that males (54.5%) are affected slightly more than females (45.5%) with Down Syndrome
• The Down Syndrome market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Down Syndrome pipeline products will significantly revolutionize the Down Syndrome market dynamics.

Down Syndrome Overview

Trisomy 21, another name for Down syndrome, is a hereditary chromosome 21 condition that causes delays in intellectual and developmental functions. It is brought on by aberrant cell division that produces more chromosomal 21 genetic material.

Get a Free sample for the Down Syndrome Market Report:

https://www.delveinsight.com/report-store/down-syndrome-market

Down Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Down Syndrome Epidemiology Segmentation:

The Down Syndrome market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Down Syndrome
• Prevalent Cases of Down Syndrome by severity
• Gender-specific Prevalence of Down Syndrome
• Diagnosed Cases of Episodic and Chronic Down Syndrome

Download the report to understand which factors are driving Down Syndrome epidemiology trends @ Down Syndrome Epidemiology Forecast

Down Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Down Syndrome market or expected to get launched during the study period. The analysis covers Down Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Down Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Down Syndrome Therapies and Key Companies

• AEF0217: Aelis Farma
• ACI-24.060: AC Immune SA
• Donepezil HCl: Eisai Inc.
• Memantine: Forest Laboratories
• E2020: Eisai Co., Ltd.
• RG1662: Hoffmann-La Roche
• ELND005: Elan Pharma
• Florbetaben (BAY94-9172): Life Molecular Imaging
• CD101: Cidara Therapeutics

Discover more about therapies set to grab major Down Syndrome market share @ Down Syndrome Treatment Market

Down Syndrome Market Strengths

• Families, advocacy groups, and healthcare organizations offer strong support networks for individuals with Down syndrome, promoting awareness, research, and inclusive policies.
• Advances in medical care and technology have improved the early detection of Down syndrome during pregnancy, allowing for better medical management and support.

Down Syndrome Market Opportunities

• Lack of approved medication for treating Down syndrome, provide pharma companies to bring novel therapies with first mover advantage.
• Technology advancements, such as assistive devices, communication aids, and accessible applications, offer opportunities to enhance communication and daily living skills for individuals with Down syndrome.

Scope of the Down Syndrome Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Down Syndrome Companies: Aelis Farma, AC Immune SA, Eisai Inc., Forest Laboratories, Eisai Co., Hoffmann-La Roche, Elan Pharma, Life Molecular Imaging, Cidara Therapeutics, and others
• Key Down Syndrome Therapies: AEF0217, ACI-24.060, Donepezil HCl, Memantine, E2020, RG1662, ELND005, Florbetaben (BAY94-9172), CD101, and others
• Down Syndrome Therapeutic Assessment: Down Syndrome current marketed and Down Syndrome emerging therapies
• Down Syndrome Market Dynamics: Down Syndrome market drivers and Down Syndrome market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Down Syndrome Unmet Needs, KOL’s views, Analyst’s views, Down Syndrome Market Access and Reimbursement 

To know more about Down Syndrome companies working in the treatment market, visit @ Down Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Down Syndrome Market Report Introduction

2. Executive Summary for Down Syndrome

3. SWOT analysis of Down Syndrome

4. Down Syndrome Patient Share (%) Overview at a Glance

5. Down Syndrome Market Overview at a Glance

6. Down Syndrome Disease Background and Overview

7. Down Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Down Syndrome 

9. Down Syndrome Current Treatment and Medical Practices

10. Down Syndrome Unmet Needs

11. Down Syndrome Emerging Therapies

12. Down Syndrome Market Outlook

13. Country-Wise Down Syndrome Market Analysis (2019–2032)

14. Down Syndrome Market Access and Reimbursement of Therapies

15. Down Syndrome Market Drivers

16. Down Syndrome Market Barriers

17.  Down Syndrome Appendix

18. Down Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/